AbbVie and Bristol Myers Squibb grabbed headlines last December with dueling, high-value acquisitions in the neuroscience space, and a pair of Phase II trial misses revealed by AbbVie on 11 November indicate that BMS may have gotten the better deal.
Key Takeaways
- AbbVie’s emraclidine failed in a pair of Phase II studies of in schizophrenia, placing the value of last year’s $8.7bn Cerevel buyout in question.
- AbbVie’s bad news may be good news for Bristol and its just-approved schizophrenia drug Cobenfy, which like emraclidine acts on muscarinic receptors
AbbVie’s emraclidine, the main source of value in its $8
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?